

NEUROENDOCRINE CANCER UK
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

NEUROENDOCRINE CANCER UK

LEGAL AND ADMINISTRATIVE INFORMATION

| | | |
|----------------------|---|---------------------------|
| Trustees | Dr R Srirajaskanthan | |
| | Mr J Kent | |
| | Mr T Jackson | |
| | Mr P Gwilliam (Chairman) | |
| | Mr D Bartlett | |
| | Ms E Brown | |
| | Mr D Ames | (Appointed 23 March 2024) |
| | Mr G Brown | (Appointed 23 March 2024) |
| Charity number | 1092386 | |
| Principal address | Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL | |
| Independent examiner | Chapman Worth Limited 2 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY | |

NEUROENDOCRINE CANCER UK

CONTENTS

| | Page |
|-----------------------------------|-------------|
| Trustees' report | 1 - 6 |
| Independent examiner's report | 7 |
| Statement of financial activities | 8 |
| Statement of financial position | 9 |
| Notes to the financial statements | 10 - 18 |

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2024

The Trustees are pleased to present the Trustees' Report and Accounts of Neuroendocrine Cancer UK (NCUK) for the year ended 30 September 2023. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in Note 1 to the Accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK (ii) excellence in support, care, treatment, and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Purpose and Need

Neuroendocrine Cancer UK (NCUK) exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are not uncommon.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, and sadness. For neuroendocrine cancer patients, specifically, the prospect of a cure is often nil, and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease, meaning their cancer pathway begins with feelings of extreme frustration. After treatment patients must address the gravity of their diagnosis at home, and often without regular access to the support of experts. Therefore, patients frequently suffer from feelings of abandonment, and struggle to know in whom to confide. Indeed, if their cancer is particularly advanced, they will face the possibility of dying. From our experience, the complexity of neuroendocrine cancer means that friends and family often struggle to comprehend their suffering.

People with a less common cancer, like neuroendocrine cancer, are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experience and to take positive and meaningful steps to address them.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Achievements and performance

The CEO is supported by the Trustee board, a full-time and part-time specialist nurse, a part-time cancer support coordinator, 2 part-time administrative assistants, a full-time operations and digital lead, part-time campaigns lead and a part-time communications officer and community fundraising officer. NCUK's psychotherapy/ counselling service is contracted to the Rare Minds organisation, and we have freelance contractors supporting occasional projects, where we do not have the expertise or resource in house.

A dedicated group of patient ambassadors also support the work of the organisation. This group flexes in numbers due to personal health situations, but the work of this group is incredibly valuable to NCUK.

This financial year has been the final year of our current 3-year strategy and completing and delivering the key activities of this strategy has been our priority. These achievements include:

- The integration and cleansing of our database to support our need for data to drive and deliver our planned new 5-year strategy.
- The development and completion of our first of its kind interactive multimedia toolkit presented to our community in the form of a flipping book. This handbook provides a complete guide to living with neuroendocrine cancer and has over 7,000 views to date.
- The launch of our patient education services in the form of monthly webinars with invited expert speakers.
- The development of our Spotlight Campaign providing topline essential information to healthcare professionals not working in the neuroendocrine field but who will undoubtedly see and treat neuroendocrine cancer patients. Understanding the unique needs of this group, ensuring referral into expertise and understanding what can be done to expedite early treatments are all aims of this campaign.

In collaboration with Rare Minds, Neuroendocrine Cancer UK developed **Conversation Openers**, an initiative born from our Open Conversations report on neuroendocrine cancer and mental health. Launched in 2022, the report underscored the critical need for healthcare professionals to engage in open dialogues with neuroendocrine cancer patients and their families regarding mental health concerns. Recognising the unique psychosocial challenges faced by individuals with neuroendocrine cancer, Conversation Openers provides healthcare professionals with practical communication strategies to navigate discussions about mental health effectively. As part of our ongoing 'Spotlight on Neuroendocrine Cancer' campaign, these 'bitesize' videos offer insights into integrating mental health considerations into routine care and initiating sensitive conversations with patients.

- Funding of a proof-of-concept research project totalling over £50,000.
- Funding a partnership with the Royal College of Surgeons to develop research around surgical treatments for neuroendocrine cancer patients. This is a 3-year programme that we support with £10,000 per year.
- Collaborating on/driven various projects to improve the collation of important data, understanding and awareness about neuroendocrine cancers. Collaborations include:

1-NHS, the National Cancer Research Institution (NCRI) and the National Cancer Registration and Analysis Service (NCRAS)

2-ENETs Centres of Excellence and expert neuroendocrine multidisciplinary teams

3- Medical and nursing societies

4-Advocacy organisations such as Cancer 52 and the International Neuroendocrine Cancer Alliance (INCA)

5-Political/ Policy agencies both in the UK, Europe and Internationally

6-Pharmaceutical industry

- Increasing our social media presence considerably
- Launching the first of its kind Ideal Patient Pathway for neuroendocrine cancer patients. This project involved a wide stakeholder group of individuals across industry, the NHS and patients. This project also had a political arm as we took the pathway to Parliament looking to engage politicians with a health interest to support, share and talk about the need for a dedicated pathway for this patient group.
- Completing our national fundraiser for our Advancing Research Campaign. This campaign saw people across the UK cold water swimming for research.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Note from the CEO Cathy Bouvier Ellis

We support all those affected by neuroendocrine cancer through our support and information work, we influence infrastructure and optimal care through our advocacy and policy work, and we address public perceptions of neuroendocrine cancer through our education and awareness work.

We do this because although we have seen an increased knowledge and understanding with respect to classification, pathogenesis, treatment, and research regarding neuroendocrine cancers, and we have seen the growth of patient advocacy and real-world data about the lived experience of the patient community, we have also witnessed, heard and listened to the significant challenges a newly diagnosed patient has to contend with - a sense of being invisible, surrounded by the unfamiliar, especially terminology, diagnostics and treatments, not conforming to the 'treatment, recovery and survivorship/decline' model of cancer care, coping with uncertainty and ultimately having to live with cancer.

Data collection, interrogation, community surveys and polls have been undertaken this year to understand the needs of our community to support the development of our new 5-year strategy. This strategy development has been a focus of the last few months and focuses the organisation on 8 key strategic adaptations:

1. Simplification of who we are with a focus on the disease name
2. A less is more approach. Project plans justified with a clear strategic objective to improve the quality of life for neuroendocrine patients and families.
3. An increased investment in our marketing and generating income programmes.
4. More engagement with our community of patient's families and HCPs to drive the relevant projects over the next 5 years
5. Develop strong and realistic workplans with clear outputs and KPIs where possible.
6. Understanding our community through excellent data management and resourcing.
7. Implement new ways of working to create a positive culture in the organisation, a sense of worth and accountability.
8. Ensure staff empowerment and engagement is a focal point with the development of clear roles and job descriptions.

Looking forward to the next 5 years, these adaptations will allow us to drive forward with our strategic priorities:

- Empower and support more people affected by neuroendocrine cancer
- Educate a wider audience with reliable accurate and data driven information
- Effectively raise awareness of neuroendocrine cancer to a defined and relevant audience
- Invest in research, through funding of a balanced & broad research programme.

We were founded by patients, families & HCP's, therefore we must continue to listen and respond to the needs of our community as a primary objective; the voice of those affected directly by neuroendocrine cancer should remain at the heart of any decisions around our future.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £239,206 (2023 £61,440) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £989,421 (2023 £750,215) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs.

Structure, governance and management

Living with Carcinoid was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. The Constitution was amended on 9th February 2006 with the association's name changed to 'NET Patient Foundation incorporating Living with Carcinoid'. On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

Trustees

Dr R Srirajaskanthan

Mr J Kent

Mr T Jackson

Mr P Gwilliam (Chairman)

Mr D Bartlett

Ms E Brown

Mr D Ames

(Appointed 23 March 2024)

Mr G Brown

(Appointed 23 March 2024)

Recruitment and appointment of trustees

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 30 SEPTEMBER 2024

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.



Mr P Gwilliam (Chairman)

Trustee

Date: 14TH JANUARY 2025

NEUROENDOCRINE CANCER UK

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2024.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA
Chapman Worth Limited
2 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY

Dated:

15 January 2025

NEUROENDOCRINE CANCER UK

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 SEPTEMBER 2024

| | | Unrestricted funds 2024 £ | Restricted funds 2024 £ | Total 2024 £ | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ |
|---|-------|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| | Notes | | | | | | |
| Income from: | | | | | | | |
| Donations and legacies | 3 | 604,451 | 105,390 | 709,841 | 472,828 | 14,195 | 487,023 |
| Charitable activities | 4 | 4,107 | - | 4,107 | - | 2,300 | 2,300 |
| Investments | 5 | 6,516 | - | 6,516 | 2,885 | - | 2,885 |
| Total income | | <u>615,074</u> | <u>105,390</u> | <u>720,464</u> | <u>475,713</u> | <u>16,495</u> | <u>492,208</u> |
| Expenditure on: | | | | | | | |
| Raising funds | 6 | 7,357 | - | 7,357 | 2,637 | - | 2,637 |
| Charitable activities | 7 | 395,938 | 77,963 | 473,901 | 369,982 | 58,149 | 428,131 |
| Total expenditure | | <u>403,295</u> | <u>77,963</u> | <u>481,258</u> | <u>372,619</u> | <u>58,149</u> | <u>430,768</u> |
| Net income | | <u>211,779</u> | <u>27,427</u> | <u>239,206</u> | <u>103,094</u> | <u>(41,654)</u> | <u>61,440</u> |
| Transfers between funds | | - | - | - | (3,520) | 3,520 | - |
| Net movement in funds | | <u>211,779</u> | <u>27,427</u> | <u>239,206</u> | <u>99,574</u> | <u>(38,134)</u> | <u>61,440</u> |
| Reconciliation of funds: | | | | | | | |
| Fund balances at 1 October 2023 | | <u>741,271</u> | <u>8,944</u> | <u>750,215</u> | <u>641,697</u> | <u>47,078</u> | <u>688,775</u> |
| Fund balances at 30 September 2024 | | <u>953,050</u> | <u>36,371</u> | <u>989,421</u> | <u>741,271</u> | <u>8,944</u> | <u>750,215</u> |

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

NEUROENDOCRINE CANCER UK

STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2024

| | Notes | 2024 £ | £ | 2023 £ | £ |
|---|-------|----------------|----------------|----------------|----------------|
| Current assets | | | | | |
| Debtors | 13 | 3,084 | | 571 | |
| Cash at bank and in hand | | 996,026 | | 759,909 | |
| | | <u>999,110</u> | | <u>760,480</u> | |
| Creditors: amounts falling due within one year | 14 | (9,689) | | (10,265) | |
| Net current assets | | | <u>989,421</u> | | <u>750,215</u> |
| The funds of the charity | | | | | |
| Restricted income funds | 16 | 36,371 | | 8,944 | |
| Unrestricted funds | 17 | 953,050 | | 741,271 | |
| | | <u>989,421</u> | | <u>750,215</u> | |

The financial statements were approved by the Trustees on 14th January 2025



Mr P Gwilliam (Chairman)
Trustee

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

3 Income from donations and legacies

| | Unrestricted funds 2024 £ | Restricted funds 2024 £ | Total 2024 £ | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ |
|---------------------|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| Donations and gifts | 456,502 | 105,390 | 561,892 | 448,030 | 14,195 | 462,225 |
| Legacies | 147,949 | - | 147,949 | 24,798 | - | 24,798 |
| | <u>604,451</u> | <u>105,390</u> | <u>709,841</u> | <u>472,828</u> | <u>14,195</u> | <u>487,023</u> |

4 Income from charitable activities

| | Unrestricted funds 2024 £ | Restricted funds 2024 £ | Total 2024 £ | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ |
|------------------------------|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| Charitable activities | | | | | | |
| Other income | 4,107 | - | 4,107 | - | - | - |
| Grants | | | | | | |
| Performance related grants | - | - | - | - | 2,300 | 2,300 |
| | <u>4,107</u> | <u>-</u> | <u>4,107</u> | <u>-</u> | <u>2,300</u> | <u>2,300</u> |

5 Income from investments

| | Unrestricted funds 2024 £ | Unrestricted funds 2023 £ |
|---------------------|------------------------------------|------------------------------------|
| Interest receivable | <u>6,516</u> | <u>2,885</u> |

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

6 Expenditure on raising funds

| | Unrestricted funds 2024 £ | Unrestricted funds 2023 £ |
|----------------------------------|------------------------------------|------------------------------------|
| Fundraising and publicity | | |
| Other fundraising costs | 7,357 | 2,637 |

7 Expenditure on charitable activities

| | Charitable activities 2024 £ | Charitable activities 2023 £ |
|--|---------------------------------------|---------------------------------------|
| Direct costs | | |
| Staff costs | 167,459 | 153,597 |
| Staff costs | 138,118 | 122,741 |
| Strategic activities | 13,932 | 11,084 |
| Computer costs | 1,563 | 4,774 |
| Advertising & marketing | 9,781 | 4,417 |
| Telephone | 2,422 | 2,850 |
| Office expenses | 5,046 | 8,187 |
| Legal & Professional | 7,069 | 3,800 |
| Other costs | 661 | 330 |
| | 346,051 | 311,780 |
| Grant funding of activities (see note 9) | 7,639 | 7,115 |
| Share of support and governance costs (see note 10) | | |
| Support | 116,324 | 105,379 |
| Governance | 3,887 | 3,857 |
| | 473,901 | 428,131 |
| Analysis by fund | | |
| Unrestricted funds | 395,938 | 369,982 |
| Restricted funds | 77,963 | 58,149 |
| | 473,901 | 428,131 |

8 Description of charitable activities

Charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

9 Grants payable

| | Charitable activities 2024 £ | Charitable activities 2023 £ |
|-------------------------|------------------------------------|------------------------------------|
| Grants to institutions: | | |
| NCUK Virtual Toolkit | 2,618 | 7,088 |
| Welfare | 5,021 | - |
| NCUK Life Alliance | - | 27 |
| | <u>7,639</u> | <u>7,115</u> |

10 Support costs allocated to activities

| | | 2024 £ | 2023 £ |
|--------------------------|-------------------------------------|----------------|----------------|
| | Basis of allocation | | |
| Staff costs | <i>Administrative staff</i> | 96,639 | 86,137 |
| Office Expenses | <i>30% of the cost (2023 13%)</i> | 2,157 | 1,208 |
| Legal & Professional | <i>32% of the cost (2023 43%)</i> | 3,378 | 2,854 |
| Computer running costs | <i>9% of the cost (2023 13%)</i> | 1,401 | 1,666 |
| Rent & Rates | <i>100% of the cost (2023 100%)</i> | 12,143 | 12,643 |
| Telecommunications | <i>5% of the cost (2023 6%)</i> | 116 | 186 |
| Other costs | <i>43% of the cost (2023 67%)</i> | 490 | 685 |
| Governance costs | | 3,887 | 3,857 |
| | | <u>120,211</u> | <u>109,236</u> |
| Analysed between: | | | |
| Charitable activities | | <u>120,211</u> | <u>109,236</u> |

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

12 Employees

The average monthly number of employees during the year was:

| 2024 Number | 2023 Number |
|-------------------|-------------------|
| 12 | 9 |
| <u> </u> | <u> </u> |

Employment costs

| | 2024 £ | 2023 £ |
|-----------------------|----------------|----------------|
| Wages and salaries | 237,497 | 216,160 |
| Social security costs | 21,507 | 19,094 |
| Other pension costs | 5,094 | 4,480 |
| | <u>264,098</u> | <u>239,734</u> |

The number of employees whose annual remuneration was more than £60,000 is as follows:

| | 2024 Number | 2023 Number |
|--------------------|-------------------|-------------------|
| > £60,000 | 1 | 1 |
| £10,000 to £60,000 | 11 | 8 |
| | <u> </u> | <u> </u> |

Remuneration of key management personnel

The remuneration of key management personnel was as follows:

| | 2024 £ | 2023 £ |
|------------------------|-------------------|-------------------|
| Aggregate compensation | 68,345 | 66,572 |
| | <u> </u> | <u> </u> |

13 Debtors

| Amounts falling due within one year: | 2024 £ | 2023 £ |
|--------------------------------------|--------------|------------|
| Other debtors | 912 | 410 |
| Prepayments and accrued income | 2,172 | 161 |
| | <u>3,084</u> | <u>571</u> |

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

14 Creditors: amounts falling due within one year

| | 2024 £ | 2023 £ |
|------------------------------------|--------------|---------------|
| Other taxation and social security | 4,938 | 4,629 |
| Trade creditors | 182 | 1,007 |
| Other creditors | 2,481 | 2,643 |
| Accruals and deferred income | 2,088 | 1,986 |
| | <u>9,689</u> | <u>10,265</u> |

15 Retirement benefit schemes

| | 2024 £ | 2023 £ |
|---|--------------|--------------|
| Defined contribution schemes | | |
| Charge to profit or loss in respect of defined contribution schemes | <u>5,094</u> | <u>4,480</u> |

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

| | At 1 October 2023 £ | Incoming resources £ | Resources expended £ | Transfers £ | At 30 September 2024 £ |
|-----------------------|---------------------------|----------------------------|----------------------------|----------------|---------------------------------|
| | <u>8,944</u> | <u>105,390</u> | <u>(77,963)</u> | <u>-</u> | <u>36,371</u> |
| Previous year: | | | | | |
| | At 1 October 2022 £ | Incoming resources £ | Resources expended £ | Transfers £ | At 30 September 2023 £ |
| | <u>47,078</u> | <u>16,495</u> | <u>(58,149)</u> | <u>3,520</u> | <u>8,944</u> |

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

| | At 1 October 2023 | Incoming resources | Resources expended | Transfers | At 30 September 2024 |
|-----------------------|------------------------------|-------------------------------|-------------------------------|------------------|-------------------------------------|
| | £ | £ | £ | £ | £ |
| General funds | 741,271 | 615,074 | (403,295) | - | 953,050 |
| | <u>741,271</u> | <u>615,074</u> | <u>(403,295)</u> | <u>-</u> | <u>953,050</u> |
| Previous year: | At 1 October 2022 | Incoming resources | Resources expended | Transfers | At 30 September 2023 |
| | £ | £ | £ | £ | £ |
| General funds | 641,697 | 475,713 | (372,619) | (3,520) | 741,271 |
| | <u>641,697</u> | <u>475,713</u> | <u>(372,619)</u> | <u>(3,520)</u> | <u>741,271</u> |

18 Analysis of net assets between funds

| | Unrestricted funds 2024 £ | Restricted funds 2024 £ | Total 2024 £ |
|------------------------------|------------------------------------|----------------------------------|--------------------|
| At 30 September 2024: | | | |
| Current assets/(liabilities) | 953,050 | 36,371 | 989,421 |
| | <u>953,050</u> | <u>36,371</u> | <u>989,421</u> |
| | | | |
| | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ |
| At 30 September 2023: | | | |
| Current assets/(liabilities) | 741,271 | 8,944 | 750,215 |
| | <u>741,271</u> | <u>8,944</u> | <u>750,215</u> |

19 Related party transactions

There were no disclosable related party transactions during the year (2023 - none).